Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01656421 |
Recruitment Status :
Completed
First Posted : August 3, 2012
Last Update Posted : May 3, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Chronic Obstructive Pulmonary Disease (COPD) |
Study Type : | Observational |
Actual Enrollment : | 767 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE) |
Actual Study Start Date : | May 2011 |
Actual Primary Completion Date : | December 2016 |
Actual Study Completion Date : | April 2019 |

Group/Cohort |
---|
COPD
Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
|
Comparators
Current or ex-smokers free from from Respiratory Disease
|
- Aortic Pulse Wave Velocity (arterial stiffness) [ Time Frame: Baseline, 2 and 5 yrs ]Rate of change in aortic pulse wave velocity in patients with COPD over a period of 5 years and its relationship to cardiovascular morbidity and mortality.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 35 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Previously Proven COPD or at risk of developing COPD
Exclusion Criteria:
- Pregnancy
- A history of malignancy in the last 5 years
- Unable to give informed consent or diagnosed dementia
- Renal or hepatic failure
- Active endocrine disorder eg., Addison's disease, hypothyroidism
- Any other disease identified as having an inflammatory or metabolic component, eg. rheumatoid disease
- Disorders affecting mobility, eg. Parkinson's disease, cerebrovascular accident.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01656421
United Kingdom | |
Cardiff Metropolitan University | |
Cardiff, United Kingdom, CF5 2YB. |
Principal Investigator: | Barry J McDonnell, PhD BSc | Cardiff Metropolitan University | |
Study Chair: | John R Cockcroft, MD, FRCP | Cardiff Metropolitan University |
Responsible Party: | Nichola Gale, Lecturer, Cardiff University |
ClinicalTrials.gov Identifier: | NCT01656421 |
Other Study ID Numbers: |
SPON 87610 10/CAD/4972 ( Other Identifier: Cardiff & Vale UHB R&D Office ) |
First Posted: | August 3, 2012 Key Record Dates |
Last Update Posted: | May 3, 2019 |
Last Verified: | May 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Lung Diseases Respiratory Tract Diseases |